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                                                ABSTRACT 
PREDICTORS OF ANEMIA AMONG HIV PATIENTS IN UGANDA 
MAY 2017 
CATHERINE S. NAGAWA, B.S., MAKERERE UNIVERSITY 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Dr. Marquis Hawkins 
HIV-related anemia is associated with increased risk of death. Prior studies suggest 
an inverse relationship between CD4 cell count and anemia, and a positive relationship 
between HIV-clinical stage and anemia. However, none have assessed the role of 
antiretroviral therapy (ART) treatment combinations in these relationships. Therefore, we 
conducted a cross-sectional study to evaluate the relationship between CD4 cell count, HIV 
clinical stage and anemia among 4803 Ugandan HIV-patients, and assessed the role of 
ART treatment combinations. We included HIV patients (> 15 years) receiving ART 
therapy combinations between 2010- 2015. We evaluated CD4 cell count and anemia using 
blood tests, and HIV-clinical staging was based upon the World Health Organization HIV-
clinical staging system. Information on ART treatment combinations was obtained from 
patients’ medical records. Multinomial logistic regression was used to model the 
relationship between CD4 cell count, HIV clinical stages and anemia. We performed a 
sensitivity analysis to examine the role of ART treatment combinations. The odds of being 
severely anemic were highest among those classified in the low CD4 cell count category 
(<200cells/µL), and those at WHO stage IV. Odds Ratios were 3.7 (95% CI; 1.48-9.26) 
and 3.2 (95% CI; 1.75-5.70), respectively. Stratification by ART treatment combinations 
 vi 
(TDF-based versus ADZ-based combination treatment) indicated an increase in the odds 
of being anemic with increase in HIV-clinical stage (stage II, OR: 1.99, 95% CI; 1.44-2.78; 
stage III, OR:3.17, 95% CI; 2.21-4.54, & stage IV, OR; 4.42, 95% CI; 2.68-7.30), for 
individuals receiving TDF-based treatment only.  Results suggest that HIV-patients with a 
low CD4 cell count and, those in advanced HIV-clinical stages should consider regular 
hemoglobin follow-up to identify and treat anemia at its earliest stages. 
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CHAPTER 1 
INTRODUCTION 
A. Human Immunodeficiency Virus 
The Human Immunodeficiency Virus (HIV) destroys CD4 cells, gradually 
damaging the immune system.1 CD4 cells are a type of white blood cells that signal 
activation of the body’s immune response upon virus detection. A higher CD4 cell count 
is indicative of a strong immune system.2 Without treatment, HIV–infected individuals 
typically progress through four  clinical stages of infection, namely; primary HIV-
infection; clinically asymptomatic stage; symptomatic HIV infection; and Acquired 
Immunodeficiency Syndrome (AIDS).3 These stages are typically referred to as HIV 
clinical stages I, II, III and IV.  
HIV clinical stage I. Primary HIV Infection (HIV clinical stage I) lasts a few 
months after infection and is often characterized with presence of Persistent Generalized 
Lymphadenopathy (PGL), that is, the enlargement of lymph nodes, in at least 2 body sites 
for a period of 6 months.  During this stage, there is a large amount of HIV in the peripheral 
blood and the immune system initiates production of HIV antibodies.  
HIV clinical stage II. Clinical asymptomatic stage (HIV clinical stage II) lasts for 
an average of ten years, and is devoid of major symptoms; however, HIV is active in the 
lymph nodes.  
HIV clinical stage III. HIV clinical stage III is also known as the symptomatic HIV 
Infection stage, and results from mild damage to the immune system marked by presence 
of HIV- related bacterial infections such as pneumonia. HIV clinical stage III develops due 
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to; 1) damaged lymph nodes; 2) increased CD4 cell destruction; and 3) failure of the 
immune system to replace destroyed CD4 cells.  
HIV clinical stage IV. HIV clinical stage IV is often referred to as AIDS, and results 
from severe damage to the immune system. At present, confirmation of AIDS diagnosis 
occurs when an HIV infected individual develops one or more HIV-related opportunistic 
infections such as cryptococci meningitis and HIV- related cancers such as Kaposi’s 
sarcoma. 
Prevalence of HIV in Uganda  
In 2015, an estimated 1.5 million Ugandans were living with HIV. HIV prevalence 
among adults, aged 15 to 49, was estimated to be 7.1% (6.6% - 7.7%). The number of 
deaths due to AIDS was estimated to be 28,000 individuals. 
The number of new HIV infection cases increased by 21% between 2005 and 
2013.4 However, there was an observed decrease of new cases between 2013 and 2015. 
Specifically, the number of new HIV infection cases reduced from 140,000 in 2013 to 
83,000 in 2015.5 The reduction in new infections has been attributed to the increased use 
of antiretroviral therapy (ART) treatments.6 ART refers to combinations of antiretroviral 
drugs that suppress HIV viral replication and prevent progression of the disease.  
B. HIV- related Anemia 
Anemia is a condition that occurs when hemoglobin levels in a person’s blood drop 
below normal. Hemoglobin is a protein molecule in the red blood cells that carries oxygen 
throughout the body.7 Normal hemoglobin levels are defined as 13 grams (g) or higher per 
deciliter (dL) of blood.8 The decrease in hemoglobin levels is due to body conditions that 
negatively influence the number of red blood cells present in the body. In HIV-patients, 
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conditions that are likely to influence red blood cell quantity are amount of  CD4 cell count 
and the level of HIV clinical stage (presence or absence of HIV-related clinical 
manifestations).9 
Prevalence of Anemia in HIV- infected individuals in Uganda 
In different clinical settings, the prevalence of HIV- related anemia among HIV-
infected individuals receiving ART varies greatly.11 Prevalence rates range from 65% to 
95% in sub-Saharan Africa12–14 and 20% to 60% in developed countries.10,15 This is due to 
differences in the prevalence of anemia risk factors; such as endemic malnutrition, 
helminthes infections and a different spectrum of opportunistic infections.11  
Established Risk Factors. Known HIV-related anemia risk factors include gender 
and type of ART medication Women, as compared to men, are more likely to develop 
anemia due to blood loss during menstruation, pregnancy and delivery.17–19 Anemia in 
HIV-infected individuals also results from the direct effect of antiretroviral agents, 
particularly zidovudine, on the hematopoietic process in the body.20 Hematopoietic is the 
process through which blood or blood cells are formed in the body.  
Sequelae of HIV-related Anemia. Anemia diagnosis in HIV-infected individuals 
has been associated with reduced quality of life,21 quick progression of HIV,14,22 decreased 
survival time,23 and increased risk for death.15 
C. Epidemiological Background 
Recent literature suggests an association between CD4 cell count, HIV- clinical 
stage and HIV –related anemia. 24–27 In particular, epidemiological research suggests a 
inverse association between CD4 cell count and anemia, 24–27 and a positive association 
between HIV- clinical stages and anemia.  
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Epidemiology of the association between CD4 cell count and anemia 
 
Between 2009 and 2016, three studies examined the relationship between CD4 cell 
count and HIV-related anemia in low–resource settings.25–28 All three studies were cross-
sectional; of these, two were single site clinic studies performed in Tanzania25 and India26. 
The third study was conducted in rural China28 using national data.  
Study findings indicate that individuals with low CD4 cell count have increased 
odds of being anemic. Odds ratios were 2.27 with 95% confidence Interval (CI) 1.33 – 
3.88), for study participants in Tanzania, 1.21 (95% CI; 1.07 – 1.3) for China and 5.0 (95% 
CI; 4.0 – 6.3) for Ethiopia. 
Although all three study findings indicate an inverse association between CD4 cell 
count and HIV-related anemia, none of the studies controlled for ART treatment in the 
analysis. Combination ART treatment has been found to be positively associated with CD4 
cell count and inversely associated with anemia.29,30 Failure to adjust for combination ART 
treatment may have underestimated the association between CD4 cell count and anemia.  
Epidemiology of the association between HIV-clinical stage and anemia 
 
One of the three studies described above assessed HIV-clinical stage as an exposure. 
This study was conducted in Tanzania, 25 and compared HIV-clinical stage classified into 
two categories (HIV clinical stage I and II versus HIV-clinical stage III and IV).  
Findings show that individuals classified in HIV-clinical stage III and HIV clinical 
stage IV were more likely to be anemic compared to those classified at HIV-clinical stage II 
and HIV-clinical stage I. Odds Ratios were 5.3 (95% CI; 3.15 – 8.9). 
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However, the relationship between HIV-clinical staging and anemia was not adjusted 
for ART treatment. Because ART treatment is positively associated with HIV-clinical stage 
and negatively associated with anemia, it is likely that this association was underestimated.  
Therefore, we conducted a cross-sectional study among Ugandan HIV-infected 
adults (N = 4803) to examine the relationship between CD4 cell count, HIV-clinical stage, 
and anemia and adjusting for ART treatment.  
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CHAPTER 2 
STUDY DESIGN AND METHODS 
A. Study Design 
We used a cross-sectional design to examined the association between CD4 cell 
count, HIV- clinical stage and anemia among HIV patients in Uganda. Data were 
electronically captured by the Ministry of Health national surveillance system between 
2010 and 2015. The Ministry of Health developed the system in 2010. The aim of the 
system is to promote the use of locally generated health data to facilitate evidence-based 
decision making on planning and resource allocation within the country’s healthcare sector.  
B. Study Population 
The study population comprised of 5276 HIV patients older than 15 years who 
received ART between 2010 and 2015 at three regional referral hospitals (RRH): 1) Hoima 
RRH in mid-western Uganda; 2) Fort-Portal RRH in western Uganda; and 3) Mubende 
RRH in central Uganda.  
Eligibility 
We excluded 1) those younger than 15 years of age (n= 287), and 2) women who 
were pregnant (n = 186). The final sample number used in the analysis is 4803 (Figure 1). 
Pregnant women were excluded from the study due to differences in physiological 
mechanisms29 and clinical definitions of anemia.  
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C. Study Methods 
Assessment of CD4 cell count  
 
  We assessed CD4 cell count as a categorical variable. Categories for CD4 cell count 
were: Low (˂ 200 cells per microliter (cells/µL); Moderate (200 - ≤ 500 cells/µL); and 
High (˃ 500 cells/µL). 
Laboratory Procedure. To obtain CD4 cell counts, we performed complete blood count 
tests at the central public health laboratory located at Makerere University. Blood was 
drawn using venipuncture and kept at ambient temperatures. The laboratory center used 
tritest reagents to determine CD4 cell count.  
Assessment of HIV Clinical Stage  
HIV clinical staging was based upon the World Health Organization (WHO) 
clinical staging system. The WHO clinical staging system is widely used in resource-
limited countries, particularly in the sub-Saharan African Region. 30, 31  To accommodate 
facilities with no or limited access to laboratory, the WHO HIV clinical staging system 
established standardized clinical guidelines for direct medical decision making, based on 
the patient’s clinical manifestations. 
Individuals are classified in WHO stage I if they have Persistent Generalized 
Lymphadenopathy PGL in at least two sites of the body for longer than 6 months.  
HIV infected individuals are classified into WHO Stage II when clinical outcomes 
include: 1) unexplained weight loss of less than 10 percent of total body weight; 2) 
recurrent respiratory infections (such as sinusitis, bronchitis, otitis media, and pharyngitis), 
and 3) range of dermatological conditions including herpes zoster flares, angular cheilitis, 
and recurrent oral ulcerations.  
8 
	
  WHO stage III signs and symptoms include: 1) weight loss of greater than 10 
percent of total body weight; 2) prolonged (more than 1 month) unexplained diarrhea; 3) 
pulmonary tuberculosis; and 4) severe systemic bacterial infections including pyomyositis, 
meningitis, bone and joint infections, and bacteremia.  
WHO stage IV includes all of the above illnesses, and presence of HIV wasting 
syndrome, Pneumocystis pneumonia (PCP), recurrent severe or radiological bacterial 
pneumonia, extra-pulmonary tuberculosis, HIV encephalopathy, CNS toxoplasmosis, 
chronic herpes simplex infection, esophageal candidiasis, and kaposi’s sarcoma. Other 
diagnostic conditions include cytomegalovirus infections, extra pulmonary cryptococcosis, 
disseminated non-tuberculous mycobacteria infection, tracheal, bronchial or pulmonary 
candida infection etc. 
In this study categories for HIV clinical stages were defined as WHO stage I, WHO 
stage II, WHO stage III and IV.  
Assessment of Anemia 
We assessed anemia using blood hemoglobin levels according to WHO hemoglobin 
cut-off points. Per WHO guidelines, non-anemic patients were described as those with > 
12 g/dl for non-pregnant women and >13 g/dl for men. Anemia severity was categorized 
as mild anemia (10 - < 13/12 g/dL), moderate anemia (8 - < 10 g/dL), and severe anemia ( 
< 8 g/dL) for both sexes.8    
Laboratory Procedures. All patients participated in a standardized laboratory assessment 
consisting of hematological tests. Hematological indices including, hemoglobin 
concentration, and red blood cell indices (mean corpuscular volume and mean corpuscular 
hemoglobin), were determined using an automated hematology analyzer - COULTER® 
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Ac·T™ 5diff CP (Cap Pierce). We categorized hemoglobin concentration according to 
WHO criteria.  
Covariates.  
We collected data on age, gender, ART, presence or absence of tuberculosis, and 
duration on ART medication from the system. Covariates were selected based on inclusion 
in prior literature 24–27 and their potential for confounding as demonstrated in previous 
findings. 
Statistical Analysis 
 
Using cross-tabulation, we assessed the unadjusted relationship between CD4 cell 
count and anemia, and HIV-clinical stage and anemia. We used chi-square tests to calculate 
p-values for categorical variables, and ANOVA for continuous variables. We used 
multinomial logistic regression to model the relationship between CD4 cell count, HIV–
clinical stages and anemia. We used a change-in-estimate approach to evaluate 
confounding. Potential confounders included age, gender, length and type of ART 
treatment, and Tuberculosis status. Covariates that caused a 10% change in coefficients for 
either CD4 cell count or HIV-clinical stage were adjusted for in the final model.  
Stratification Analysis. We assessed anemia dichotomously (anemic vs non-
anemic) and stratified study participants based on type of ART treatment received, those 
with missing data on type of ART treatment were excluded. Therefore, study participants 
were classified as receiving either a AZT- or TDF- based treatment combination (n = 4457). 
We calculated adjusted odds ratios (OR) and 95% confidence intervals to determine the 
strength of associations between the CD4 cell count, HIV clinical stage and anemia.  
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CHAPTER 3 
RESULTS 
Characteristics of the Study Population. 
A total of 4803 HIV positive individuals (1668 males and 3135 females), receiving 
ART treatment therapy combinations between 2010-2015, were used to examine the 
relationship between CD4 cell count, HIV clinical stage and anemia. The mean age and 
standard deviation (mean ± S.D) of the study participants was 38.9 ± 10.5 years, with a 
range of 15 to 94 years. The median CD4 count was 220.0 cells/µL (IQR: 27 – 295). Thirty-
four percent of the study participants were classified at WHO stage 1, 36% at WHO stage 
II, 24% WHO stage III, and 6.1% as WHO stage IV. Approximately 68% of the study 
participants reported receiving HIV treatment for a duration of 3 years or less, only 3% 
reported tuberculosis medication use. Sixty percent of the study participants were using 
AZT-based treatment combination (Table 2). 
Prevalence of Anemia  
Anemia was present in 28.8% of the study participants. Prevalence of mild, 
moderate and severe anemia were 20.6%, 4.5% and 3.7%, respectively. Gender was 
significantly associated with anemia (P-value < 0.001) with gender-specific prevalence 
rates of 30% (female) and 23.2% (males). CD4 cell count significantly decreased with 
increase in anemia severity levels (P- value < 0.001); that is, the mean ± SD CD4 cell count 
for study participants with no anemia, mild, moderate and severe anemia were 236.6 ± 
210.2, 194.2 ± 145, 143.1 ± 135.2 and 147.1 ± 142.2, respectively. Prevalence of anemia 
differed significantly by WHO clinical stage; for example, study participants with mild 
anemia comprised of 30% of individuals categorized at WHO stage 1, 42% at WHO stage 
11 
	
II, 23% at WHO clinical stage III, and 5.6% at WHO clinical stage IV. Within the severe 
anemia category, about 18% were at WHO stage I, 30% at WHO stage II, 39% at WHO 
stage III & 13% at WHO stage IV (Table 2).  
ART treatment type was significantly associated with anemia. Almost half of the 
study participants with severe anemia (48%) reported using a TDF-based treatment, and 
62% of those categorized as having mild anemia reported using AZT-based treatment. 
(Table 2)  
The mean CD4 cell count decreased with increase in anemia severity; for instance, 
individuals with no anemia had a mean CD4 cell count of 236.6 (201.2), and those with 
mild anemia had a mean CD4 cell count of 194 (145). Anemia was most prevalent among 
individuals at WHO stage II (Table 2). 
CD4 cell count and Anemia 
Mild anemia. Compared to individuals with high CD4 cell count, those with 
moderate CD4 cell count (>200 - ≤ 500 cells/uL) were 94% more likely to be mildly anemic 
(OR, 1.94, 95% CI: 1.28 - 2.93), and those with a low CD4 cell count had a 2-fold increase 
in odds of being mildly anemic (OR, 3.12, 95% CI: 2.18 – 4.47) (Table 2).  
Moderate anemia. Compared to study participants with high CD4 cell count, those with 
moderate CD4 cell count had a 3-fold increase in odds of having moderate anemia (OR, 
3.21, 95% CI: 1.60 – 3.65). Those with a low CD4 cell count had a 6-fold increase in odds 
of having moderate anemia (OR, 6.10, 95% CI: 2.21 – 16.78). 
Severe anemia. Compared to those with a high CD4 cell count, a moderate CD4 cell count 
was insignificantly associated with increased odds of having severe anemia (OR: 1.92; 
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95% CI: 0.752 – 4.89), and those with a low CD4 cell count had a 3-fold increase in odds 
of having severe anemia (OR, 3.70, 95% CI: 1.48 – 9.26). 
HIV clinical stages and Anemia 
  Mild anemia. Using study participants at WHO stage I as a reference group, those 
at WHO clinical stage II were 29% (OR: 1.29, 95% CI: 1.08 – 1.54) more likely to have 
mild anemia. WHO clinical stage III and IV were not statistically significantly associated 
with having mild anemia, the odds ratios are 0.93 (95% CI: 0.76 – 1.16) and 1.22 (95% CI: 
0.88 – 1.71) respectively.  
Moderate anemia. Compared to study participants in WHO stage I, those at WHO clinical 
stage 1I had increased odds of having moderate anemia (OR, 1.29, 95% CI: 0.94 – 2.07). 
Those at WHO clinical stage III and WHO stage IV had a 2-fold increase of having 
moderate anemia with odds ratios of 2.28 (95% CI: 1.53 – 3.38) and 2.16 (95% CI: 1.23 – 
3.79), respectively.   
Severe anemia. Compared to study participants in WHO stage I, those at WHO clinical 
stage II were 62% more likely to have severe anemia (OR, 1.62, 95% CI: 1.03 – 2.55), and 
those at WHO clinical stage III were at a 2-fold increase of having severe anemia (OR, 
2.72, 95% CI: 1.73 – 4.29). Those at WHO clinical stage IV had a 3-fold increase of having 
severe anemia (OR, 3.16, 95% 1.75 – 5.70).  
We examined the joint effect of CD4 cell count and HV on anemia(yes/no) and 
found that individuals with a lower CD4 cell count and at higher HIV clinical stages had 
increased odds of having anemia compared to those with a high CD4 cell count and at 
lower HIV-clinical stages (Figure 2). 
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Sensitivity Analysis 
When we stratified the study participants per treatment received, we found that 64% 
of the study participants were receiving AZT-based treatment, and had relatively lower 
CD4 cell counts with a mean of 192 (138). On average, those receiving the AZT-based 
treatment were older (40yrs. ± 10.4) than those receiving TDF-based treatment (36yrs. 
± 10). Most of the study participants receiving TDF-based treatment were at HIV clinical 
stage 1 (44%), while most of those receiving AZT-based treatment were at HIV clinical 
stage II (Table 3). 
Results from the stratified analysis indicate a statistically significant trend of 
increasing anemia with increasing HIV clinical stage among individuals receiving TDF-
based treatment only. Compared to those classified at WHO stage I, those at WHO stage 
II were 99% more likely to be anemic (OR, 1.99; 95% CI: 1.44 – 2.77), those at WHO 
stage III had a 3-fold increase of being anemic (OR, 3.17; 95% CI: 2.21 – 4.53), and those 
at WHO stage IV had a 4-fold increase (OR; 4.42; 95% CI: 2.68 – 7.29) compared to those 
receiving AZT-based regimen within the same stage.  
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CHAPTER 4 
DISCUSSION 
A. Primary Findings 
 In this study population, prevalence of anemia was 28.8%. Females had a 
significantly higher prevalence of anemia compared to males. 
CD4 cell count. We found that HIV-infected patients with low CD4 cell count (< 200 
cells/µl) had a significant increase in the odds of being anemic, compared to those with 
high CD4 cell count (> 500 cells/µl).  
HIV clinical staging. In comparison to the WHO stage 1, study results suggest that patients 
at advanced HIV clinical stages (WHO stage IV) had increased odds of 1.22, 2.16 and 3.16 
of having mild, moderate and severe anemia, respectively. This is in line with the study 
research hypothesis. 
Joint effect of the two exposures. When we examined the joint effect of CD4 cell 
count and HIV clinical stage on anemia and found similar trends of the association. That 
is, those with lower CD4 cell counts and at higher HIV clinical stages had increased odds 
of having anemia compared to those with higher counts, at lower clinical stages. 
The findings suggest that CD4 cell count may be predictive of early anemia onset 
(mild or moderate anemia), and HIV clinical stages may be more predictive of severe 
anemia. Additionally, study findings suggest that CD4 cell count is inversely associated 
with anemia, and HIV clinical stages are positively associated with anemia, which is in line 
with the research hypothesis.  
Our study findings are consistent with results of Gunda et al. and Yin et al. who 
reported that anemia was more prevalent among patients in the most advanced stages of 
15 
	
HIV. And also, consistent with the results of Levine et al. and Volberding et al. who 
reported that more severe levels of anemia are found among HIV- infected individuals 
exhibiting low CD4 cell counts. 
We found that for individuals receiving TDF-based treatment, the odds of being 
anemic increased with an increase in HIV clinical stage. Absence of a similar association 
among those receiving AZT-based treatment may be due to survivor bias. It is quite 
possible that individuals receiving this treatment are deceased, and therefore were not 
present to be selected for inclusion in the study. Possible explanations for increased risk 
for death in the AZT-based treatment subgroup are; 1) AZT-based treatments are 
recommended for women at childbearing age to prevent mother-to-child HIV transmission 
and, 2) one of AZT’s known health side effects is anemia. Given that the female gender 
and AZT are established risk factors for anemia, the observed findings may be explained 
by differences in the characteristics of individuals receiving a particular treatment (AZT 
versus TDF). Therefore, interpretation of the finding that there is an increase in the odds 
of being anemic with increase in HIV clinical stage within the TDF-based treatment 
subgroup only, should be precautious and further investigated prospectively.  
To our knowledge, this is the first study to assess the relationship between CD4 cell 
count, HIV clinical stage and anemia, and control for ART treatment combinations. This 
approach provides more precise measures compared to those shown in prior research and 
adds to the existing literature on the association between CD4 cell count, HIV clinical stage 
and anemia among HIV –infected adults. 
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B. Physiological Mechanisms 
CD4 cell count. The physiologic association between CD4 cells and anemia among 
HIV-infected individuals can be explained through two basic mechanisms; 1) reduced red 
blood cell production, and 2) increased red blood cell destruction. First, CD4 cell 
destruction caused by HIV infection leads to a disruption in the levels of natural chemicals 
and normal functioning of the bone marrow, which in turn, reduces production of red blood 
cells and therefore may lead to anemia. Secondly, CD4 cell destruction leads to a faulty 
immune system where groups of disorders produce autoantibodies that attack the body’s 
own red blood cells, thus increasing red blood cell destruction, which may lead to anemia. 
HIV clinical staging.  Blood loss and infection of the bone marrow may contribute 
to the physiologic relation between HIV-clinical stage and anemia. Neoplastic diseases in 
HIV infected individuals such as Kaposi’s sarcoma, atypical mycobacteria, Hodgkin’s 
lymphoma and non-Hodgkin’s Lymphoma infect the bone marrow directly, or lead to 
gastrointestinal blood loss that in turn reduces the number of red blood cells in the body 
which may lead to anemia. 
C. Study Strengths and Limitations 
Non-Differential Misclassification of CD4 Cell Count 
We obtained CD4 cell counts for all study participants using complete blood count 
tests performed at the central public health laboratory at Makerere University. Complete 
blood count test is standard for establishment of CD4 cell count.32 Therefore, non-
differential misclassification of CD4 cell count is unlikely to occur. If present, we would 
expect an underestimation of the relationship between CD4 cell count and anemia with bias 
towards the null. 
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Non-Differential Misclassification of HIV-Clinical Stage 
 
For this study, HIV–clinical staging is based upon WHO HIV-clinical staging 
system. WHO HIV-clinical staging is  widely used in low-resource settings.33,31 However, 
the system relies on clinical manifestations of HIV, rather than laboratory confirmatory 
tests. Therefore, non-differential misclassification of exposure (HIV clinical stage) is 
highly likely. Bias due to non-differential misclassification will lead underestimation of 
the true OR with bias towards the null. 
Selection bias 
Selection bias would occur if anemic patients with low CD4 cell count and those at 
advanced stages of HIV were more likely to participate in the study. This would occur if 
such patients were aware of the study hypothesis, and were more inclined to participate in 
a study on this topic. Because participants were randomly selected from the ministry of 
health surveillance system (eliminating any form of self-selection into the study), selection 
bias is unlikely to occur. 
Information Bias 
 
Information bias could occur if one’s anemia status influenced collection of 
information on exposure variables (CD4 cell count and HIV- clinical stage). It is highly 
unlikely that information bias occurred in this study because data from all participants 
(regardless of exposure status) was collected through routine medical visits, and captured 
by the ministry of health surveillance system, from which it was extracted for this study.  
Non-Differential Misclassification of Anemia  
 
Hemoglobin levels were obtained through blood tests performed at the central 
public health laboratory at Makerere University. Anemia definition was per WHO criteria 
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for hemoglobin concentration in the blood. Although hemoglobin concentration in blood 
is acceptable for anemia diagnosis,34 it is considered insufficient.35 More recently, it’s been  
argued that evaluation of hemoglobin levels jointly with reticulocyte count, bilirubin and 
mean corpuscular volume is better for anemia diagnosis.36 Therefore, non-differential 
misclassification of anemia is possible, causing an underestimation of the study results with 
a bias towards the null value. The magnitude of this effect may be moderate as hemoglobin 
concentrations are generally accepted standard for anemia diagnosis for HIV-infected 
individuals.35 
Confounding 
 
 We did not have data on iron intake which is a potential confounder for the 
relationship between CD4 cell count and anemia. Due to iron’s independent inverse 
relationship with both CD4 cell count and anemia, bias due to confounding is likely and 
may result into an overestimation of the study results. However, the impact of such bias on 
the study results is expected to be minor because nutritional habits (the major source of 
iron) may not vary greatly among individuals in this region. 
Temporal sequence 
Due to the cross-sectional nature of the study, information on the exposures (CD4 
cell count and HIV–clinical stage) and outcome of interest (anemia) were collected at the 
same point in time. Therefore, we cannot ascertain whether the exposures led to anemia, 
or alternatively, if anemia influenced the exposures. This is particularly true for HIV 
clinical stage. For example, it is more likely that patients were categorized into HIV clinical 
stage III&IV because they exhibited anemia symptoms.  
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On the contrary, it is unlikely that anemia would cause a reduction in CD4 cell 
count considering the uniqueness of the study population (HIV-infected individuals). The 
biological mechanism through which the HIV-virus operates in the body may describe a 
causal pathway between CD4 cell and anemia. When the body is infected with HIV, the 
virus directly destroys CD4 cells. CD4 cell destruction results into a fragile immune system 
that adversely affects red blood cell count, likely leading to anemia.39 Therefore, among 
HIV-infected individuals, it is highly unlikely that a low CD4 cell count may result from 
anemic conditions, and because no prior literature suggests such an association, we expect 
the impact of this bias to be minor. 
For this cross-sectional study, a proper temporal sequence needed to ascertain 
causality between HIV –clinical stage and anemia will not be firmly established. 
Survivor Bias 
 
Survivor bias would occur if HIV- patients with very low CD4 cell count were more 
likely to die from severe anemic conditions, and therefore could not be included in the 
study sample. Similarly, if those with high HIV-clinical stages III&IV were more likely to 
die because of severe anemia.  It is possible that our study results were underestimated due 
to this bias. The odds ratio of severely anemic patients (OR: 3.7) is lower than that of 
moderately anemic patients (OR: 6.10), this was not as expected and is likely due to 
survivor bias.  
D. Conclusion 
In HIV- infected individuals, a low CD4 cell count and advanced clinical stages are 
associated with anemia. Although our analyses cannot show whether this relationship is 
causal, our findings are consistent with prior studies that have assessed this relationship. 
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Consideration should be given to evaluating CD4 cell count, HIV clinical stage and anemia 
in a prospectively to address the issue of issue of survivor bias. From a clinical standpoint, 
the results suggest that patients with low CD4 cell count and those in advanced HIV clinical 
stages, should have regular hemoglobin follow up to identify anemia at its earliest stages.  
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Figure 1. Exclusion Criteria 
 
 
	 	 	 	 	 	 	 	 	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 	 	 	 	 	 	 	 	
	 	 	
	
	
	
	
	
	
	
	
	
	 	 	 	 	 	
Excluded 
Pregnant	women	(n	=	186) 
 
Total	number	of	HIV	patients	 
(N	=	5276) 
Adult	HIV	patients 
(n	=	4989) 
Excluded 
Younger	than	15	years 
(n	=	287) 
Final	sample	 
(n =	4803) 
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Table 1. Distribution of covariates per Anemia status among Ugandan HIV patients 2010-2015 
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Table 2. Adjusted Odds Ratios and 95% confidence intervals for CD4 cell count, HIV clinical stage, and Anemia in HIV 
patients 2010-2015 
     
Mild anemia vs No 
Anemia 
Moderate anemia vs No 
Anemia 
Severe anemia vs No 
Anemia 
     (n = 941) (n = 215) (n = 176) 
     OR 95% CI OR 95% CI OR 95% CI 
           
CD4 cell counts            
High (> 500 cells/µL) 37 1.00 referent 1.00 referent 1.00 referent 
Moderate (200 - ≤ 500 cells/µL) 510 1.94 1.28 - 2.93 3.21 1.15 - 8.93 1.92 0.75- 4.89 
Low (< 200 cells/µL) 785 2.41 1.60 -  3.65 6.10 2.22- 16.77 3.70 1.48 - 9.26 
p-trend      < 0.001  < 0.001  < 0.001 
 
WHO HIV - clinical staging         
WHO stage I 365 1.00 referent 1.00 referent 1.00 referent 
WHO stage II 516 1.29 1.08 - 1.54 1.39 0.94 - 2.07 1.62 1.03 - 2.55 
WHO stage III 349 0.93 0.76 - 1.16 2.28 1.53 - 3.38 2.72 1.73 - 4.29 
WHO stage IV 102 1.22 0.88 - 1.71 2.16 1.23 - 3.79 3.16 1.75 - 5.70 
p-trend     < 0.001  < 0.001  < 0.001 
               
Model adjusted for age, gender and antiretroviral therapy combinations     
Abbreviations: CI, Confidence Interval; WHO, World Health Organization       
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Figure 2. Odds Ratios and 95% Confidence Intervals of the joint effect of CD4 cell count and Anemia (yes/no) 
 
1Figure 
                                                
1 Study participants were classified into 12 groups as shown above. 
0.00
5.00
10.00
15.00
20.00
1 2 3 4 5 6 7 8 9 10 11 12
1. High	CD4	cell	count	and	WHO	Stage	I	(n	=	163) 
2. High	CD4	cell	count	and	WHO	Stage	II	(n	=77)	
3. High	CD4	cell	count	and	WHO	Stage	III	(n	=	46)	
4. High	CD4	cell	count	and	WHO	Stage	IV	(n	=	16)	
5. Moderate	CD4	cell	count	and	WHO	Stage	1	(n	=	947)	
6. Moderate	CD4	cell	count	and	WHO	Stage	II	(n	=	751)	
7. Moderate	CD4	cell	count	and	WHO	Stage	III	(n	=	311)	
8. Moderate	CD4	cell	count	and	WHO	Stage	IV	(n	=	73)	
9. low	CD4	cell	count	and	WHO	Stage	I	(n	=538)	
10. low	CD4	cell	count	and	WHO	Stage	II	(n	=	899)	
11. low	CD4	cell	count	and	WHO	Stage	III	(n	=	776)	
12. low	CD4	cell	count	and	WHO	Stage	IV	(n	=	206)	
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Table 3. Distribution of characteristics of study participants for each treatment   
combination 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristics  
 
TDF - based treatment 
  
AZT - based treatment 
Number of study participants 1589 2868 
Age mean (SD) 36.7 (10) 40.2 (10.4) 
CD4 cell count mean (SD) 286 (246.9) 191.68 (137.7) 
Duration on ART treatment (yrs.) 1.7 (0.8) 2.3 (1.02) 
Gender (Female)  65% 64% 
HIV clinical stage             
WHO stage I 
WHO stage II 
WHO stage III 
WHO stage IV 
 
700 (44%) 
484 (30%) 
309 (19%) 
96 (6%) 
 
870 (30%) 
1126 (40%) 
709 (25%) 
163 (9%) 
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Table 4. Odds Ratios and 95% Confidence Intervals for HIV clinical stage and Anemia 
(yes/no) in HIV patients 2010-2015 stratified by ART treatment therapy. 
 
 
    
      Adjusted* 
  non-cases anemia cases OR 95% CI 
AZT-based treatment (n = 2868)        
WHO stage I 614 256 1.00 referent 
WHO stage II 747 379 1.23 1.02 - 1.50 
WHO stage III 498 211 1.04 0.83 - 1.30 
WHO stage IV 113 50 1.09 0.76 - 1.58 
TDF - based treatment (n = 1589)        
WHO stage I 621 79 1.00 referent 
WHO stage II 380 104 1.99 1.44 - 2.78 
WHO stage III 204 105 3.17 2.21 - 4.54 
WHO stage IV 57 39 4.42 2.68 - 7.30 
Abbreviations: AZT, Azido-thymidine; TDF, Tenofovir disoproxil   
*Adjusted for Gender and CD4 cell count      
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